Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments

Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.

While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.

Study In Multiple Myeloma

The company said that the first clinical data for its CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.

The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.

Study In B-cell non-Hodgkin lymphoma

Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company said. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.

“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.

Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around CRBU stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.

CRBU stock is up 52% this year and approximately 3% over the past 12 months. 

Read also: Ford Sales In US Rise 1.6% In October On Continued Truck Demand

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on